(Q34543171)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

review article

1 reference

title

N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

author name string

Alessandro Minarini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Silvia Ferrari

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Martina Galletti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Nina Giambalvo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Daniela Perrone

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Giulia Rioli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

language of work or name

English

0 references

publication date

2 November 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

26 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

page(s)

279-292

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic strategies to prevent contrast-induced acute kidney injury.

26 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Glutathione: a novel treatment target in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Prodrug approach for increasing cellular glutathione levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Systematic review of N-acetylcysteine in the treatment of addictions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Redox paradox: effect of N-acetylcysteine and serum on oxidation reduction-sensitive mitogen-activated protein kinase signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

The chemistry and biological activities of N-acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine for the treatment of glutathione deficiency and oxidative stress in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Is cocaine desire reduced by N-acetylcysteine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Low Pretreatment Impulsivity and High Medication Adherence Increase the Odds of Abstinence in a Trial of N-Acetylcysteine in Adolescents with Cannabis Use Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

The role of cystine-glutamate exchange in nicotine dependence in rats and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

A randomized controlled pilot trial of oral N-acetylcysteine in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Acetylcysteine for treatment of autism spectrum disorder symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine as treatment for self-injurious behavior in a child with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Effects of N-acetyl cysteine on cognitive function in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine for major depressive episodes in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Effects of N-Acetyl cysteine on suicidal ideation in bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine in the Treatment of Trichotillomania

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

21 January 2018

Skin picking disorder

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine in the treatment of skin-picking disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetyl cysteine in the treatment of grooming disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Glutamatergic dysfunction in skin-picking disorder: treatment of a pediatric patient with N-acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Cigarette smoking during an N-acetylcysteine-assisted cannabis cessation trial in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Oxidative stress in psychiatric disorders: evidence base and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Oxidative stress in Rett syndrome: natural history, genotype, and variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Oxidative stress markers in bipolar disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Glutamatergic substrates of drug addiction and alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Pharmacotherapy for trichotillomania

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

The neurochemical circuitry of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Micronutrients, N-acetyl cysteine, probiotics and prebiotics, a review of effectiveness in reducing HIV progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-Acetylcysteine reverses cocaine-induced metaplasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Chronic N-acetylcysteine during abstinence or extinction after cocaine self-administration produces enduring reductions in drug seeking

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

An in vivo and in vitro study on the protective effects of N-acetylcysteine on mitochondrial dysfunction in isoproterenol treated myocardial infarcted rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Mitochondrial involvement in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

System x(c)(-) regulates microglia and macrophage glutamate excitotoxicity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Effect of hemorrhagic shock on gut barrier function and expression of stress-related genes in normal and gnotobiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

The glutamate homeostasis hypothesis of addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Glutamate transporter GLT-1 mediates N-acetylcysteine inhibition of cocaine reinstatement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Cystine/glutamate exchange serves as the source for extracellular glutamate: modifications by repeated cocaine administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Effects of N-acetyl-L-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine modulates hallucinogenic 5-HT(2A) receptor agonist-mediated responses: behavioral, molecular, and electrophysiological studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Management of anaphylactoid reactions to intravenous N-acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

S-nitrosothiols signal hypoxia-mimetic vascular pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Facilitation action of N-acetylcysteine on the anticonvulsant effect of sodium valproate in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Status epilepticus after a massive intravenous N-acetylcysteine overdose leading to intracranial hypertension and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Clinical pharmacokinetics of N-acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Pharmacokinetics of N-acetylcysteine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Massive acetylcysteine overdose associated with cerebral edema and seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Lidocaine absorption and metabolism after oropharyngeal application in young and young-elderly adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1251580

10.1080/17425255.2017.1251580

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27766914%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference